Previous 10 | Next 10 |
When pharmaceutical companies manage to get highly positive results from clinical trials of one of their more important products, then it almost always has a positive impact on the stock price, and that is what happened with MDCO stock. Solid Boost The Medicines Company (NASDAQ:MDCO) an...
Gainers: Abeona Therapeutics (NASDAQ: ABEO ) +79% . Cidara Therapeutics (NASDAQ: CDTX ) +56% . Ardelyx (NASDAQ: ARDX ) +33% . Quorum Health Corporation (NYSE: QHC ) +21% . Net Element (NASDAQ: NETE ) +19% . Conn's (NASDAQ: CONN ) +18% . Cassava Sciences (NASDAQ: SAVA ) +15% . ...
The Medicines Company (NASDAQ: MDCO ) is up 17% premarket on light volume in response to its announcement of positive results from a Phase 3 clinical trial, ORION-11 , evaluating inclisiran, administered twice per year, for lowering "bad" cholesterol (LDL-C) in patients with a...
- Inclisiran achieved 54% LDL-C lowering with time-adjusted reductions of 50% sustained over 18 months of treatment - ORION-11 study demonstrates inclisiran’s excellent safety profile, including no treatment-related liver or renal abnormalities - Full study res...
The Medicines Co. ( MDCO ) announced that it had achieved the primary and key secondary endpoints for its late-stage study using inclisiran to treat patients with atherosclerotic cardiovascular disease ((ASCVD)) or ASCVD-risk equivalents along with elevated bad cholesterol despite maximu...
Back in May, Esperion Therapeutics ( ESPR ) announced the FDA set two PDUFA dates in February for the company's two leading products, bempedoic acid and bempedoic acid/ezetimibe combination tablet. Both of these product candidates are looking to be approved to treat elevated low-density lipo...
Shares of The Medicines Company (NASDAQ: MDCO) jumped 13.8% on Monday after the biotech announced that Orion-11, a clinical trial testing inclisiran in patients with high levels of LDL cholesterol, was successful. Interestingly, shares of Alnylam Pharmaceuticals (NASDAQ: ALNY) , w...
Arcadia Biosciences (NASDAQ: RKDA ) +21% on high fiber wheat deal . More news on: Arcadia Biosciences, Inc., The Medicines Company, Pitney Bowes Inc., Stocks on the move, Read more ...
The Medicines Company (NASDAQ: MDCO ) announces positive results from a Phase 3 clinical trial, ORION-11 , evaluating twice-yearly dosing of inclisiran aimed at reducing LDL-C ("bad" cholesterol) in patients with atherosclerotic cardiovascular disease. More news on: The Medicines Compan...
ORION-11 study met all primary and secondary efficacy endpoints with efficacy consistent with Phase 1 and 2 studies Safety profile of inclisiran was at least as favorable as in ORION-1 Phase 2 and ORION-3 open-label extension studies Detailed data will be presented...
News, Short Squeeze, Breakout and More Instantly...
The Medicines Company Company Name:
MDCO Stock Symbol:
NASDAQ Market:
The Medicines Company Website:
The Medicines Company (the “Company”) today provided notice of a Make-Whole Fundamental Change to holders of its (i) 2.50% Convertible Senior Notes due 2022 (the “2022 Notes”), (ii) 2.75% Convertible Senior Notes due 2023 (the “2023 Notes”) and (ii) 3...
Shares of Meritor (NYSE: MTOR) , a global supplier of drivetrain, braking, and other aftermarket automotive solutions for vehicles, jumped as high as 16% Tuesday morning after markets digested the announcement that Meritor will join the S&P SmallCap 600 index. The announcement actually c...
NEW YORK , Dec. 30, 2019 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the open of trading on Monday, January 6 : NexPoint Residential Trust Inc. (NYSE: NXRT) will replace Avon Products Inc. (NYSE: AVP). Natura...